fusidic acid has been researched along with itraconazole in 5 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (itraconazole) | Trials (itraconazole) | Recent Studies (post-2010) (itraconazole) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 249 | 4 | 108 |
| Protein | Taxonomy | fusidic acid (IC50) | itraconazole (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.89 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.7 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.666 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.4256 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.2 | |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 2.5676 | |
| Cruzipain | Trypanosoma cruzi | 3 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 3.476 | |
| C-C chemokine receptor type 4 | Homo sapiens (human) | 3.2689 | |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | 3.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for fusidic acid and itraconazole
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
4 other study(ies) available for fusidic acid and itraconazole
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |